Explain this page
Arphra AIPlain-English read on Actinium Pharmaceuticals, Inc.’s valuationNo recent stories.
today
- Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer15d
- Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer15d
- Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models15d
- Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models15d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $11.07 (+974.76%)
Candlestick · 1Y
Open in chart workstation →ATNM
1.00-18.03%H 1.38L 0.95MA50 1.14MA200 —Avg vol 119K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.98% | 0.00% | -11.97% | -6.36% | -35.22% | -24.26% | -29.45% | -87.04% | -87.17% | -98.06% | -97.71% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$1.01
1 sh
Bid
$0.92
30 sh
Ask
$1.23
100 sh
Spread
$0.310
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Technology+2.51%
- Communication Services+1.85%
- Utilities+1.35%
- Consumer Defensive-0.30%
- Industrials-0.32%
- Energy-0.45%
- Basic Materials-0.66%
- Financial Services-0.67%
- Real Estate-0.67%
- Healthcare-1.51%
- Consumer Cyclical-1.74%
Top industries (issuer's industry highlighted)
- Biotechnology-3.87%
- Trucking-5.25%
- Advertising Agencies-5.20%
- Medical - Equipment & Services+5.08%
- Grocery Stores-4.35%
- Computer Hardware-3.67%
- Electronic Gaming & Multimedia+3.56%
- Coal-3.56%
- Communication Equipment-3.51%
- REIT - Diversified-3.43%
- Other Precious Metals-3.35%
- Integrated Freight & Logistics-3.29%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancerprnewswire.com·Jun 03, 2026
- Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancerprnewswire.com·Jun 03, 2026
- Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Modelsprnewswire.com·Jun 03, 2026
- Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Modelsprnewswire.com·Jun 03, 2026
- Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimizationprnewswire.com·May 06, 2026
Peers
No peer list available for ATNM.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|